Skip to main content
Research Microscopy Solutions
USA
back
Research Microscopy Solutions
recommended searches
popular searches

Flexible Leasing for Microscopes

Investing in cutting-edge microscopy technology is crucial for scientific advancement. However, high upfront costs can create financial barriers, especially for biopharma companies looking to optimize drug discovery and development.

ZEISS offers flexible leasing and financing solutions, which enables biotech, pharmaceutical, and research institutions to access world-class imaging systems without the financial strain of high upfront costs.

Sample Prep & Education/Routine
Get in touch

Why lease a microscope?

Access cutting-edge solutions without heavy upfront investment

Overcome high costs

Traditional microscopy investments can be a financial strain for biotech startups and companies with capital constraints, limiting their ability to stay ahead in drug discovery. Here’s why leasing can be a smarter alternative:

  • High capital costs limit access to state-of-the-art technology, delaying innovation.
  • Restricted competitiveness due to outdated imaging solutions in drug development.
  • Delays and complexity when outsourcing imaging services for biomarker discovery.
  • Rapid technological advancements make existing systems obsolete, impacting research efficiency.
  • Ongoing maintenance expenses add to long-term costs, reducing financial flexibility.

Transform your investment

By leasing through ZEISS, you transform your microscopy investment from a capital expenditure to an operating expense with ZEISS flexible financing options. High capital costs limit access to state-of-the-art technology, delaying innovation.

  • Predictable payments and lower upfront costs: Spread costs over time for predictable expenses, crucial for research funding cycles.
  • Access to the latest imaging technology: Upgrade to next-generation ZEISS systems for high-resolution drug discovery and biomarker analysis.
  • Preserve capital and reduce risk: Preserve capital for R&D and clinical trials while accessing advanced imaging systems.
  • Ideal for biopharma startups and growing labs: Reduce upfront investment and scale microscopy capabilities as research demands evolve.
  • Comprehensive training and support: Optimize microscopy workflows for pharmaceutical research with expert guidance.

 

*All leasing and financing requests are subject to credit approval and eligibility assessment in accordance with ZEISS financial policies.

Why Biopharma leaders choose ZEISS for imaging excellence

Empower your research and accelerate discovery with our flexible capital leasing service

  • Global leader in microscopy

    With over a century of expertise in microscopy innovation, ZEISS is trusted by leading biopharma companies for high-resolution imaging solutions that drive drug discovery and biomarker research. Our advanced microscopy systems provide unparalleled precision, supporting preclinical studies, cellular analysis, and molecular imaging essential for pharmaceutical breakthroughs.

  • Seamless technology upgrades

    Stay ahead of the rapidly evolving pharmaceutical landscape with the regular equipment upgrades. Through our leasing program, you have access to the latest imaging upgrades. These options ensure access to the latest imaging advancements without major reinvestment. Regular equipment upgrades ensure that your research stays at the cutting edge, keeping pace with emerging industry trends and regulatory demands.

  • Dedicated service & support

    Our industry-leading specialists provide comprehensive training, application support, and workflow optimization, ensuring reliable and high-performance pharmaceutical imaging. With ZEISS, you gain an imaging solution and a strategic partner in your drug discovery and development journey.

Leasing & financing pans for Biotech & Pharma

Empower your research and accelerate discovery with our flexible capital leasing service

  • Capital lease

    Own your equipment over time

    Request a capital lease

    Benefits

    • Structured as an asset purchase with ownership at lease end.
    • Flexible 3-5-year terms tailored for biopharma research cycles.
    • Includes application support & training to accelerate drug discovery workflows.
    • Potential tax benefits (subject to regional regulations).

  • Operating lease

    Maximum flexibility without ownership

    Request an operating lease

    Benefits

    • ZEISS retains ownership, reducing financial risk for biopharma companies.
    • Functions like an equipment rental with no long-term commitment.
    • Flexible 1–3-year lease terms, aligning with research project timelines.
    • Includes expert support & training for seamless integration into biopharma workflows.
    • Potential tax advantages (depending on location).

  • Applications services & consulting

    Leverage our expertise
    Applications services & consulting

    Services

    • AI-powered imaging analysis tools for drug screening and target identification.
    • Customizable microscopy as a service plans.
    • Expert application specialists ensure seamless integration into pharmaceutical workflows.
Request a Demo

Configure your Axioscan 7 for Spatial Biology

Workflow automation for spatial biology at scale

The new Axioscan 7 Spatial Biology Configuration is designed to maximize efficiency, accuracy, and reproducibility for multiplex immunofluorescence (mIF) and high-throughput spatial biology workflows.

Configure your Axioscan 7 for Spatial Biology

Biopharma insights hub

Discover tailored applications

Explore applications and discover tailored solutions for you industry needs.

Explore applications & insights